<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is an uncommon but serious complication of patients who undergo autologous bone marrow transplantation (auto-BMT) for non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> or <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Some patients exhibit an indolent course, but others succumb to <z:e sem="disease" ids="C0001807" disease_type="Mental or Behavioral Dysfunction" abbrv="">aggressive disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>p53 overexpression is rare in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> but common in therapy-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We used an immunostaining method to analyze expression of p53, the p53-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene products, MDM2, p21waf1, <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> gene protein (pRB), and the antiapoptotic oncoprotein bcl-2 before and after BMT in BM specimens from eight patients with clonal karyotypic abnormalities characteristic of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Staining was compared with findings in <z:mpath ids='MPATH_458'>normal</z:mpath> BM specimens and specimens from auto-BMT controls and patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>p53 protein was found in three (75%) of four post-transplantation specimens from patients in whom a clinically aggressive form of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> developed </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, p53 was absent in <z:hpo ids='HP_0000001'>all</z:hpo> of the specimens from four patients with karyotypic evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but with indolent disease </plain></SENT>
<SENT sid="7" pm="."><plain>bcl-2 protein was overexpressed by immature myeloid cells in seven of eight pre-BMT specimens </plain></SENT>
<SENT sid="8" pm="."><plain>After BMT, it was predominantly found at low levels in cases positive for p53 </plain></SENT>
<SENT sid="9" pm="."><plain>MDM2 was present only after transplantation and was found with equal frequency in patients with indolent and aggressive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>We detected p21waf1 in only one aggressive post-BMT <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> specimen </plain></SENT>
<SENT sid="11" pm="."><plain>pRB was normally expressed in <z:hpo ids='HP_0000001'>all</z:hpo> of the specimens </plain></SENT>
<SENT sid="12" pm="."><plain>These data show that p53 and bcl-2 staining patterns in post-transplantation <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are similar to those described in therapy-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>p53 positivity is associated with poor prognosis in auto-BMT patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Expression of MDM2, p21waf1, and pRB in this group of patients is not helpful in predicting outcome </plain></SENT>
</text></document>